Spyre Therapeutics Inc (SYRE)

Date: O: H: L: C: Vol:

Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Operating Expenses	8.77%41.64	45.64	57.17	56.89	41.94
Operating Income/Loss	8.77%-41.64	-45.64	-57.17	-56.89	-41.94
Nonoperating Income/Loss	123.28%5.44	-23.36	-5.36	45.71	5.22
Income/Loss From Continuing Operations Before Tax	47.54%-36.20	-69.01	-62.53	-11.18	-36.72
Income Tax Expense/Benefit	-	-	-	-	-
	47.54%-36.20	-69.01	-62.53	-11.18	-36.72
Attributable To Parent	47.54%-36.20	-69.01	-62.53	-11.18	-36.72